Abstract：
UNASSIGNED: Idiopathic granulomatous mastitis (IGM) is a benign inflammatory breast disease, commonly presented with a sensitive breast lump and developing scars. Currently, there is no definitive treatment for IGM but Antibiotics, steroids, immunosuppressive drugs or a surgical treatments are the usual options. This case series aimed to evaluate the effectiveness of cotrimoxazole in treatment of IGM as there is no clinical consensus on the best and most widely acknowledged therapeutic management for IGM.
METHODS: All IGM patients were treated by Cotrimoxazole (800 mg BD for one week), and they were assessed at a month, 3 months, and 6 months after that. The primary outcome was an improvement in presenting complaints and symptoms such as palpable mass, bulging, pain, erythema and hypersensitivity of breast skin, breast discharge and fluctuation. The secondary outcome was the refractory rate within 6 months. Number of 20 patients were included. At the baseline, participants exhibited various symptoms such as bulging, pain and erythema (100 %), breast discharge (80 %), and fluctuation (30 %). After the intervention, there was a significant decrease in the prevalence of symptoms over the study period. The prevalence of bulging and pain, erythema, discharge, and fluctuation symptoms were decreasedto 5 %, 0 %, and 0 %, respectively. The refractory rate of IGM within six months of cotrimoxazole treatment was estimated 30 %.
UNASSIGNED: In this study, the treatment approach did not involve corticosteroids and invasive procedures and the recurrence rate of IGM within the six months was lower than in similar studies that employed steroids alone or any more invasive treatments. Additionally, our study showed a high healing rate with resolution of inflammation, pain, discharge, and fluctuation. These results suggest that cotrimoxazole may be a more favorable option than high-dose corticosteroids and a comparable alternative to low-dose corticosteroids regarding recurrence rates.
CONCLUSIONS: Cotrimoxazole may be an effective treatment option for idiopathic granulomatous mastitis. However, further research is needed on different treatment options.
METHODS: All IGM patients were treated by Cotrimoxazole (800 mg BD for one week), and they were assessed at a month, 3 months, and 6 months after that. The primary outcome was an improvement in presenting complaints and symptoms such as palpable mass, bulging, pain, erythema and hypersensitivity of breast skin, breast discharge and fluctuation. The secondary outcome was the refractory rate within 6 months. Number of 20 patients were included. At the baseline, participants exhibited various symptoms such as bulging, pain and erythema (100 %), breast discharge (80 %), and fluctuation (30 %). After the intervention, there was a significant decrease in the prevalence of symptoms over the study period. The prevalence of bulging and pain, erythema, discharge, and fluctuation symptoms were decreasedto 5 %, 0 %, and 0 %, respectively. The refractory rate of IGM within six months of cotrimoxazole treatment was estimated 30 %.
UNASSIGNED: In this study, the treatment approach did not involve corticosteroids and invasive procedures and the recurrence rate of IGM within the six months was lower than in similar studies that employed steroids alone or any more invasive treatments. Additionally, our study showed a high healing rate with resolution of inflammation, pain, discharge, and fluctuation. These results suggest that cotrimoxazole may be a more favorable option than high-dose corticosteroids and a comparable alternative to low-dose corticosteroids regarding recurrence rates.
CONCLUSIONS: Cotrimoxazole may be an effective treatment option for idiopathic granulomatous mastitis. However, further research is needed on different treatment options.
摘要：
■特发性肉芽肿性乳腺炎（IGM）是一种良性炎症性乳腺疾病，通常表现为敏感的乳房肿块和发展中的疤痕。目前,除了抗生素，IGM没有明确的治疗方法，类固醇,免疫抑制药物或手术治疗是通常的选择。本病例系列旨在评估复方新诺明治疗IGM的有效性，因为在IGM的最佳和最广泛认可的治疗管理方面尚无临床共识。
方法：所有IGM患者均接受复方新诺明（800mgBD治疗一周）治疗，他们在一个月的时候被评估，3个月,在那之后6个月.主要结果是出现投诉和症状的改善，例如可触知的肿块，鼓胀,疼痛,红斑和乳房皮肤过敏，乳房分泌物和波动。次要结果是6个月内的不应率。包括20名患者。在基线，参与者表现出各种症状，如鼓胀，疼痛和红斑（100％），乳房分泌物(80%)，和波动（30%）。干预之后,在研究期间,症状患病率显著下降.鼓胀和疼痛的患病率，红斑,放电,波动症状下降到5%，0%,0%,分别。在复方新诺明治疗的六个月内，IGM的难治率估计为30％。
■在这项研究中，治疗方法不涉及皮质类固醇和侵入性手术,并且IGM在6个月内的复发率低于单独使用类固醇或任何更多侵入性治疗的类似研究.此外,我们的研究表明，随着炎症的消退，愈合率很高，疼痛,放电,和波动。这些结果表明，与高剂量皮质类固醇相比，复方新诺明可能是更有利的选择，并且在复发率方面与低剂量皮质类固醇相比具有可比性。
结论：复方新诺明可能是治疗特发性肉芽肿性乳腺炎的有效选择。然而,需要进一步研究不同的治疗方案.
方法：所有IGM患者均接受复方新诺明（800mgBD治疗一周）治疗，他们在一个月的时候被评估，3个月,在那之后6个月.主要结果是出现投诉和症状的改善，例如可触知的肿块，鼓胀,疼痛,红斑和乳房皮肤过敏，乳房分泌物和波动。次要结果是6个月内的不应率。包括20名患者。在基线，参与者表现出各种症状，如鼓胀，疼痛和红斑（100％），乳房分泌物(80%)，和波动（30%）。干预之后,在研究期间,症状患病率显著下降.鼓胀和疼痛的患病率，红斑,放电,波动症状下降到5%，0%,0%,分别。在复方新诺明治疗的六个月内，IGM的难治率估计为30％。
■在这项研究中，治疗方法不涉及皮质类固醇和侵入性手术,并且IGM在6个月内的复发率低于单独使用类固醇或任何更多侵入性治疗的类似研究.此外,我们的研究表明，随着炎症的消退，愈合率很高，疼痛,放电,和波动。这些结果表明，与高剂量皮质类固醇相比，复方新诺明可能是更有利的选择，并且在复发率方面与低剂量皮质类固醇相比具有可比性。
结论：复方新诺明可能是治疗特发性肉芽肿性乳腺炎的有效选择。然而,需要进一步研究不同的治疗方案.
